eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | retinal vein occlusion |
| Comorbidity | |macular edema |
| Sentences | 176 |
| PubMedID- 25347799 | Effect of intravitreal injection of dexamethasone implant on corneal endothelium in macular edema due to retinal vein occlusion. |
| PubMedID- 24696869 | They offer an alternative route in the management of macular edema due to uveitis, retinal vein occlusion, diabetes and pseudophakia. |
| PubMedID- 20432959 | Purpose: to examine the short-term effects of intravitreal injections of bevacizumab on macular edema due to central retinal vein occlusion (crvo). |
| PubMedID- 21652108 | Conclusion: patients with macular edema due to retinal vein occlusions, who received a single intravitreal injection of triamcinolone acetate less than 6 months after the diagnosis, displayed both anatomical and functional improvement, whereas patients injected more than 6 weeks after the diagnosis of macular edema showed a cmt reduction but with less improvement in visual acuity. |
| PubMedID- 22653545 | Macular sensitivity and morphology after intravitreal injection of triamcinolone acetonide for macular edema with branch retinal vein occlusion. |
| PubMedID- 20429890 | Conclusions: these results suggest that the vitreous level of vascular endothelial growth factor might influence the visual prognosis and the response of macular edema to vitrectomy in patients with branch retinal vein occlusion. |
| PubMedID- 22668313 | Purpose: to investigate the visual and anatomical effects of intravitreal bevacizumab treatment of macular edema due to central retinal vein occlusion (crvo). |
| PubMedID- 21784203 | Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion. |
| PubMedID- 25223207 | Subjects and methods: twenty seven eyes of 27 patients who had undergone vitrectomy for macular edema associated with branch retinal vein occlusion (brvo), proliferative diabetic retinopathy (pdr), macular hole (mh)/epiretinal membrane (erm) at toho university sakura medical center were studied. |
| PubMedID- 23411880 | Objective: to evaluate the association between vitreous fluid levels of inflammatory factors and macular edema in patients with branch retinal vein occlusion (brvo). |
| PubMedID- 22925843 | Purpose: to evaluate the efficacy of bevacizumab injection used secondarily in patients with macular edema due to central retinal vein occlusion after failure of intravitreal triamcinolone acetonide injection. |
| PubMedID- 20714746 | Background: we investigated whether pigment epithelium-derived factor (pedf) or vascular endothelial growth factor (vegf) influence macular edema in patients with branch retinal vein occlusion (brvo). |
| PubMedID- 24828198 | Intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion persisting despite multiple intravitreal bevacizumab injections. |
| PubMedID- 24894397 | Role of soluble vascular endothelial growth factor receptors-1 and -2, their ligands, and other factors in branch retinal vein occlusion with macular edema. |
| PubMedID- 22153634 | Recurrence of macular edema in retinal vein occlusions after treatment with intravitreal ranibizumab (lucentis). |
| PubMedID- 22481482 | Purpose: to investigate how combined cystoid spaces and serous retinal detachment affect photoreceptor status and visual acuity at final visit in macular edema associated with branch retinal vein occlusion. |
| PubMedID- 22095093 | Retinal sensitivity after resolution of the macular edema associated with retinal vein occlusion. |
| PubMedID- 23629796 | Conclusion: our study showed efficacy and safety of intravitreal dexamethasone implant in the treatment of macular edema due to retinal vein occlusion. |
| PubMedID- 24205253 | The geneva (global evaluation of implantable dexamethasone in retinal vein occlusion with macular edema) study evaluated the safety and efficacy of an intravitreal dexamethasone implant 0.7 mg versus an implant 0.35 mg versus sham injection in both brvo and crvo. |
| PubMedID- 25748280 | Methods: this is a multicenter, comparative, interventional, retrospective study that included 74 patients who were initially treated with intravitreal bevacizumab and later received either dex or ta for the treatment of recalcitrant cystoid macular edema due to retinal vein occlusion. |
| PubMedID- 24311895 | Ranibizumab is now fda approved for the treatment of age-related macular degeneration as well as macular edema associated with retinal vein occlusion. |
| PubMedID- 19967679 | Purpose: aqueous levels of vascular endothelial growth factor (vegf) and interleukin-6 (il-6) are associated with the severity of macular edema in patients with central retinal vein occlusion (crvo). |
| PubMedID- 26383643 | Recurrence of macular edema in eyes with branch retinal vein occlusion changes the diameter of unaffected retinal vessels. |
| PubMedID- 21402982 | An eye from 8 patients diagnosed as having macular edema due to branch retinal vein occlusion received an injection, after having received topical anesthesia, of 0.2 ml of ape, which had been obtained using a simplified method. |
| PubMedID- 20738886 | Background: this study investigated whether soluble intercellular adhesion molecule-1 (sicam-1) has a role in the pathogenesis of macular edema associated with branch retinal vein occlusion (brvo) together with vascular endothelial growth factor (vegf). |
| PubMedID- 21500185 | Results: nine eyes of 9 consecutive patients treated with a total of 9 sustained-release dexamethasone 0.7 mg intravitreal implants for macular edema associated with retinal vein occlusion were included. |
| PubMedID- 20453544 | The outcome of vitrectomy for macular edema was examined in patients with central retinal vein occlusion (crvo), as well as whether vascular endothelial growth factor (vegf) and interleukin-6 (il-6) levels in vitreous fluid influence the visual prognosis and macular edema. |
| PubMedID- 24068204 | The mechanisms responsible for macular edema with branch retinal vein occlusion (brvo) remain to be elucidated. |
| PubMedID- 24830824 | Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion. |
| PubMedID- 23842103 | Purpose: to evaluate the association between vitreous fluid levels of inflammatory factors and macular edema in patients with central retinal vein occlusion (crvo). |
| PubMedID- 22653439 | Background: to evaluate the baseline spectral-domain optical coherence tomography (sd-oct) characteristics of macular edema (me) due to branch retinal vein occlusion (brvo) for visual outcome after intravitreal bevacizumab injection. |
| PubMedID- 21350277 | A comparative study between intravitreal triamcinolone and bevacizumab for macular edema due to central retinal vein occlusion with poor vision. |
| PubMedID- 21478810 | Conclusion: these results suggest that a rebound of macular edema in eyes with branch retinal vein occlusion was more likely to occur when the intravitreal bevacizumab therapy is initiated before the macular edema reaches the maximum level. |
| PubMedID- 24876761 | Treatment of systemic hypertension is important for improvement of macular edema associated with retinal vein occlusion. |
| PubMedID- 23046435 | Changes of inflammatory factors after intravitreal triamcinolone acetonide for macular edema with central retinal vein occlusion. |
| PubMedID- 22492175 | Methods: we studied the relationship between foveal sensitivity, obtained as the "foveal threshold" by use of humphrey perimetry, and best-corrected visual acuity, converted to the logarithm of the minimum angle of resolution (logmar), for 117 eyes with epiretinal membrane (erm), 197 eyes with retinal vein occlusion associated with macular edema (rvome), and 158 eyes with central serous chorioretinopathy (csc). |
| PubMedID- 21744123 | Lamellar macular hole formation in chronic cystoid macular edema associated with retinal vein occlusion. |
| PubMedID- 22183139 | Recurrence of macular edema associated with branch retinal vein occlusion after intravitreal bevacizumab. |
| PubMedID- 25634982 | Purpose: the association between aqueous humor levels of various growth/inflammatory factors or cytokines and the severity of macular edema was investigated in patients with central retinal vein occlusion (crvo). |
| PubMedID- 20103055 | Methods: ninety-one eyes of 91 patients with macular edema associated with retinal vein occlusion had undergone a comprehensive ophthalmologic examination, including measurement by spectral-domain oct. |
| PubMedID- 21337043 | Sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (report 1). |
| PubMedID- 25336905 | Direct photocoagulation to leakage points to treat chronic macular edema associated with branch retinal vein occlusion: a pilot study. |
| PubMedID- 24526927 | The ozurdex dexamethasone-sustained delivery implant has been approved by the united states food and drug administration (fda) for the treatment of macular edema associated with retinal vein occlusion (rvo) and for noninfectious posterior uveitis. |
| PubMedID- 22474425 | The dexamethasone drug delivery system (dds) [ozurdex, allergan, irvine, california] is a biodegradable, sustained-release device approved by the us fda for the treatment of macular edema associated with retinal vein occlusion and noninfectious posterior segment uveitis. |
| PubMedID- 22553416 | The formation of lmh has been described in patients with diabetic cystoid edema and in chronic cystoid macular edema associated with retinal vein occlusion. |
| PubMedID- 23433821 | We report the case of anterior chamber migration of a dexamethasone implant (ozurdex((r))) in a 54-year-old woman with macular edema due to a central retinal vein occlusion. |
| PubMedID- 25092480 | Purpose: to report our results concerning the safety and efficacy of repeated sustained-release dexamethasone 0.7 mg implants (ozurdex, allergan, inc., irvine, ca) in patients with persistent macular edema (me) due to retinal vein occlusion (rvo) previously treated with anti- vegf injections. |
| PubMedID- 23179231 | Intravitreal bevacizumab has been adopted as a well-established treatment modality for the treatment of macular edema associated with branch retinal vein occlusion. |
| PubMedID- 23629792 | Conclusion: intravitreal injections of bevacizumab and ranibizumab improved the visual acuity and the central foveal thickness in macular edema due to retinal vein occlusion at 3 months. |
| PubMedID- 23255086 | Purpose: to evaluate the functional and structural changes of extrafoveal macula after intravitreal bevacizumab (ivb) injection in patients with macular edema due to branch retinal vein occlusion (brvo) using multifocal electroretinogram (mferg) and optical coherence tomography (oct). |